September 7-9, 2017
Chicago, IL

View SH/EAHP Workshop Program


Program Committee

Workshop Review Panel

Robert Hasserjian, MD,  Massachusetts General Hospital Dan Arber, MD
Olga Weinberg, MD, Children's Hospital Boston Magdalena Czader, MD, PhD
Frank Kuo, MD, PhD, Brigham and Women's Hospital Falko Fend, MD
  Megan Lim, MD, PhD
  Miguel Piris MD
  Frank Kuo, MD, PhD
  Olga Weinberg, MD
  Robert Hasserjian, MD

Types of Cases Sought for Workshop

1. Otherwise typical myeloid or lymphoid neoplasm with unusual / unexpected genetic findings


  • Myelodysplastic syndromes with mutations more typical of other myeloid neoplasms
  • Unexpected genetic profile in WHO AML or ALL entities
  • Follicular lymphoma with unusual genetic findings
  • Competitor masked neoplastic processes uncovered by genetic profiling

2. Myeloid or lymphoid neoplasm That Are Difficult to classify with clarifying genetic findings as provisional genetically-defined entities in the 2016 WHO Classification


  • Leukocytosis (atypical CML versus CNL) where mutation analysis helps confirm the diagnosis
  • Hairy cell leukemia versus splenic marginal zone lymphoma resolved by BRAF mutation or NOTCH2
  • AML with Runx1 mutation and AML with BCR-ABL1
  • BCR-ABL1-like ALL defined by specific mutations or Translocations
  • Acute leukemia with ambiguous typical immunophenotype with myeloid or lymphoid Genetic Alterations
  • Process That Appears non-neoplastic where genetic profiling Helped establishement a neoplastic diagnosis (eg hypereosinophilia with clonal abnormality, myelodysplastic syndromes diagnosis established by abnormal cytogenetics)

3. Incidental or preclinical clonal myeloid or lymphoid proliferations detected by genetic analysis


  • Clonal hematopoiesis or indeterminate potential (CHIP), Idiopathic cytopenia or undetermined significance (ICUS) and clonal cytopenia or undetermined significance (CCUS)
  • Monoclonal gammopathy of undetermined significance (MGUS)
  • Monoclonal B-cell lymphocytosis
  • In situ follicular neoplasia

4. Germline mutations or familial syndromes predisposing to myeloid or lymphoid neoplasms


  • Myeloid neoplasms with germline Runx1, ETV6 or GATA2 mutations
  • AML with germ-line mutations CEBPA
  • JMML associated with Noonan syndrome

Deadline for submission is February 28, 2017. Early submissions are strongly encouraged. Please follow all online and mailing requirements for each case: Notice of workshop acceptance will be sent by May 27, 2017.


To submit a case for the SH Workshop 2017, please go to:


More about

Sign in